AstraZeneca and Incyte to study cancer drugs together
LONDON May 14 (Reuters) - AstraZeneca has signed a clinical study collaboration with U.S. biotech company Incyte , highlighting its desire to push ahead with drug development despite an unwanted $106 billion bid approach from Pfizer.
The agreement will test a combination of two different drugs designed to boost the immune system to help it fight tumours - AstraZeneca's MEDI4736 and Incyte's INCB24360 - in a Phase I/II clinical study, the British firm said on Wednesday.
- French warplanes search Mali desert for crashed Air Algerie plane
- At least 15 die in Israeli shelling of Gaza school as toll exceeds 750 |
- Exclusive: Ukraine rebel commander acknowledges fighters had BUK missile
- Sierra Leone's chief Ebola doctor contracts the virus
- Minnesota man asked to leave Southwest flight after critical tweet